Neurocrine Biosciences Inc.

$96.58 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About Neurocrine Biosciences Inc.

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Stock Analysis

last close $96.58
1-mo return 2.1%
3-mo return -10.3%
avg daily vol. 1.97M
52-week high 136.27
52-week low 86.02
market cap. $8.8B
forward pe 31.4
annual div. -
roe 46.2%
ltg forecast 33.2%
dividend yield -
annual rev. $1.0B
inst own. 96.7%
baraka

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist